ATNM — Actinium Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $40.87m
- -$32.02m
Annual income statement for Actinium Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 1.14 | 1.03 | 0.081 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Total Operating Expenses | 22.4 | 26.1 | 35.1 | 52 | 42.1 |
| Operating Profit | -22.4 | -25 | -34.1 | -51.9 | -42.1 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -22.2 | -24.8 | -33 | -48.8 | -38.2 |
| Net Income After Taxes | -22.2 | -24.8 | -33 | -48.8 | -38.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -22.2 | -24.8 | -33 | -48.8 | -38.2 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -22.2 | -24.8 | -33 | -48.8 | -38.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.83 | -1.2 | -1.37 | -1.83 | -1.27 |